# Junta clínica — PT-pseudo_dcd61cf9b443 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_dcd61cf9b443",
  "pid": "PT-pseudo_dcd61cf9b443",
  "task": 1,
  "psa": 8.3,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 0.215,
  "psav": 1.64,
  "psap": 7.9,
  "vol": 38.54,
  "dre": "Suspicious",
  "bx": "Positive",
  "cspca": 0.86351734,
  "medhx": "COPD, Chronic kidney disease",
  "meds": "ciprofloxacine",
  "notes": "PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.",
  "pmhx": [
    "COPD",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "63 kg",
    "height": "170 cm",
    "bmi": "21.8",
    "bp": "111/75 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (37 pack-yr, quit 2012)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile."
    },
    {
      "s": "History",
      "t": "Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension."
    }
  ],
  "occupation": "retired primary school teacher",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Vascular surgery — varicose veins consult",
    "Gastroenterology — surveillance colonoscopy"
  ],
  "alcohol": "33 units / week (heavy)",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 6/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd61cf9b443
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.215 ng/mL²
  - PSA velocity: 1.64 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 38.54 mL
  - Months since last PSA: 2
  - DRE findings: Suspicious (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86351734 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease
  - Problem list / PMHx: COPD, Chronic kidney disease
  - Current medication: ciprofloxacine
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.

Vitals: weight 63 kg, height 170 cm, BMI 21.8, BP 111/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2012).

Chief complaint: Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile.

History: Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012.

Physical examination: DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension.

Patient info: retired primary school teacher; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 33 units / week (heavy); exercise Cycling 2x/week, ~20 km; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult; Gastroenterology — surveillance colonoscopy.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.41
  uncertainty  +/- 0.18 epistemic (95% band 0.07-0.76); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  2. distance 0.32: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"
  3. distance 0.36: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: pirads=important, bx=important, psa=important, age=important, comorbidity=noted, psad=noted, dre=important, vol=noted, fh=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated if there is a lesion on MRI that mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is not decisive because the guideline does not account for the documented grade of the prior biopsy, which is a key factor in determining management. The cohort criterion confirms that the panel does not determine the decision because the documented grade of the prior biopsy and the surveillance history are what decide.

WHAT WE STILL NEED
The prior biopsy status is documented as "Positive" on the panel, which is crucial because the guideline requires histopathology criteria to trigger a change in management. The documented grade of the prior biopsy and the number and dates of biopsy sessions are needed to determine if a repeat biopsy is indicated.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and history of the prior biopsy, which is the key missing piece according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsy sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior prostate biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study? The discrete focus measures roughly "18 x 14 x 12 mm" in the "left peripheral zone", and post-contrast dynamics show "brisk, localized enhancement compared to adjacent tissue".
psa_trend
What is the serial PSA value trend (rising, flat, or falling)? The trend shows values of "5.8 ng/mL" on "Jan 2023", "3.7 ng/mL" on "Jan 2024", and "8.3 ng/mL" on "Jan 2025", indicating a rising trend.
previous_notes
What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsy sessions, and surveillance protocol status? The notes mention a "PSA concentration of 7.9 ng/mL" on "22 Jan 2024" and a referral for evaluation, but the documented prior biopsy grade, number of sessions, and surveillance protocol status are not explicitly stated.
laboratory_results
What are the full panel results, including free-PSA fraction, renal function, and haemoglobin? The Free PSA is "1.71 ng/mL" with a "%Free PSA" of "21%" on "29 Dec 2024". Renal function shows "Creatinine" of "128 umol/L" and "eGFR" of "<60 mL/min/1.73m2". Haemoglobin is "15.2 g/dL".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes did not contain any information regarding the family history of prostate cancer.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 classification on the MRI.
Rising PSA trend from 3.7 ng/mL to 8.3 ng/mL.
DRE findings described as "Suspicious" with an "irregular nodule".
EAU guideline notes that a repeat biopsy is mandated if a lesion mandates it to confirm histological progression.
AGAINST sampling this patient now
The prior biopsy status is documented as "Positive" on the panel, which is crucial because the guideline requires histopathology criteria to trigger a change in management.

WHERE THIS LEANS
The findings strongly suggest a need to re-evaluate the tissue status given the high-risk MRI finding and rising PSA, which aligns with the EAU guideline's requirement for histological criteria.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 8.30 ng/mL over 3 points spanning 24 months; velocity +1.25 ng/mL per year; doubling time about 46 months.
PROJECTION at 6 months: 10.6 ng/mL, conformal 95% band 3.0-36.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.42
  uncertainty  +/- 0.19 epistemic (95% band 0.04-0.80), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.41  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.42  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.11  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: pirads=important, bx=important, psa=important, age=important, comorbidity=noted, psad=noted, dre=important, vol=noted, fh=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes explicitly state that the documented prior biopsy grade, number of sessions, and surveillance protocol status are not explicitly stated.

ALIGNMENT WITH THE PANEL
The retrieved evidence does not directly overturn the PANEL-PROTOCOL's answer of NO BIOPSY, as the critical information required by the EAU guideline—the documented grade of the prior biopsy—remains unretrieved.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior prostate biopsy? This question remains unanswered by the retrieved documents.
Q2. What is the number and dates of prior biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due? This question also remains unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The documented grade of the prior biopsy and the surveillance protocol status carry the most weight because the EAU guideline explicitly requires histological criteria to trigger a change in management, which is precisely what is missing. The rising PSA trend and PI-RADS 5 are important but secondary to the documented tissue status.

MY SUGGESTION TO THE CHAIR
Given that the critical information required by the guideline to override the panel's decision is missing, the case cannot be decided yet. We must defer until the registrar retrieves the specific details regarding the prior biopsy grade and surveillance status.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The panel protocol suggested no biopsy based on an identical precedent in the labelled series, but the Verifier indicated the decision is not ready because the documented grade of the prior biopsy is missing. The rising PSA trend (from 3.7 to 8.3 ng/mL) and PI-RADS 5 are important factors, but the lack of documented histological information prevents a definitive decision. Therefore, the case cannot be decided yet, and a deferral is appropriate pending retrieval of the prior biopsy grade.

What carried weight: pirads=important, bx=important, psa=important, age=important, comorbidity=noted, psad=noted, dre=important, vol=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
